VALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Patients with a clinical diagnosis of depression   │ Patients with a clinical diagnosis of depression   │     100 │
│ who in the judgement of their physician require    │ who in the judgement of their physician require    │         │
│ medication management may be eligible for          │ medication management may be eligible for          │         │
│ enrollment. A score of 10 or more on the PHQ-9     │ enrollment. A score of 10 or more on the PHQ-9     │         │
│ instrument will be required for enrollment         │ instrument will be required for enrollment         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Some practices utilize the PHQ-2 and PHQ-9 are     │ Some practices utilize the PHQ-2 and PHQ-9 are     │     100 │
│ part of routine screening for depression. If the   │ part of routine screening for depression. If the   │         │
│ tests are performed routinely, they do not need to │ tests are performed routinely, they do not need to │         │
│ be repeated for study eligibility, and may be      │ be repeated for study eligibility, and may be      │         │
│ performed prior to informed consent for this       │ performed prior to informed consent for this       │         │
│ study. If, however, the PHQ-9 is not routinely     │ study. If, however, the PHQ-9 is not routinely     │         │
│ performed, informed consent must be performed      │ performed, informed consent must be performed      │         │
│ prior to administration. Patients with a score     │ prior to administration. Patients with a score     │         │
│ below 10 will be considered screen failures and    │ below 10 will be considered screen failures and    │         │
│ will not be enrolled or offered the MYnd testing   │ will not be enrolled or offered the MYnd testing   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients with non-psychotic comorbid conditions    │ Patients with non-psychotic comorbid conditions    │     100 │
│ may be included                                    │ may be included                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients must be either medication treatment naïve │ Patients must be either medication treatment naïve │     100 │
│ for behavioral illnesses or have no active         │ for behavioral illnesses or have no active         │         │
│ medication treatments for at least 1 month prior   │ medication treatments for at least 1 month prior   │         │
│ to enrollment. Prohibited medications at the time  │ to enrollment. Prohibited medications at the time  │         │
│ of enrollment will include stimulants,             │ of enrollment will include stimulants,             │         │
│ benzodiazepines and THC. Prior therapy with these  │ benzodiazepines and THC. Prior therapy with these  │         │
│ agents is permitted with a washout of \>30 days    │ agents is permitted with a washout of >30 days     │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients must have private medical insurance       │ Patients must have private medical insurance       │     100 │
│ coverage through Horizon Blue Cross Blue Shield.   │ coverage through Horizon Blue Cross Blue Shield.   │         │
│ This is limited to insured commercial members,     │ This is limited to insured commercial members,     │         │
│ including HMO, and excluding, for the avoidance of │ including HMO, and excluding, for the avoidance of │         │
│ doubt, members of self-insured customers or        │ doubt, members of self-insured customers or        │         │
│ Medicare or Medicaid programs                      │ Medicare or Medicaid programs                      │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Diagnosis of a psychotic disorder                  │ Diagnosis of a psychotic disorder                  │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History of, or current, open head brain trauma.    │ History of, or current, open head brain trauma.    │     100 │
│ Candidates with any metal, shrapnel or other       │ Candidates with any metal, shrapnel or other       │         │
│ similar objects in the head that could affect the  │ similar objects in the head that could affect the  │         │
│ QEEG                                               │ QEEG                                               │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History of: craniotomy, cerebral metastases,       │ History of: craniotomy, cerebral metastases,       │     100 │
│ cerebrovascular accident; current diagnosis of     │ cerebrovascular accident; current diagnosis of     │         │
│ seizure disorder, schizophrenia, schizo-affective  │ seizure disorder, schizophrenia, schizo-affective  │         │
│ disorder, dementia, mental retardation, or major   │ disorder, dementia, mental retardation, or major   │         │
│ depression with psychotic features; or use of      │ depression with psychotic features; or use of      │         │
│ depot neuroleptics in last 12 months               │ depot neuroleptics in last 12 months               │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Uncontrolled thyroid disorders                     │ Uncontrolled thyroid disorders                     │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Known pregnancy and/or lactation, or intent to     │ Known pregnancy and/or lactation, or intent to     │     100 │
│ become pregnant during this study                  │ become pregnant during this study                  │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Chronic or acute pain requiring prescription pain  │ Chronic or acute pain requiring prescription pain  │     100 │
│ medication(s) (narcotic or synthetic narcotic)     │ medication(s) (narcotic or synthetic narcotic)     │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Participation in any other therapeutic drug study  │ Participation in any other therapeutic drug study  │     100 │
│ within 60 days preceding inclusion                 │ within 60 days preceding inclusion                 │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒═══════════════════════════════════╤═══════════════════════════════════╤═════════╕
│ Personal Criteria                 │ CHIA Criteria                     │   Score │
╞═══════════════════════════════════╪═══════════════════════════════════╪═════════╡
│ Must have minimum age of 18 Years │ Diagnosis of a psychotic disorder │      30 │
╘═══════════════════════════════════╧═══════════════════════════════════╧═════════╛

CHIA has no unique criteria

Levenshtein Ratio of Entire trial at once: 99
Average Levenshtein Ratio of individual lines: 94.61538461538461
OverAll Ratio: 96.8076923076923
